Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Recruiting · Phase 4 · NCT06834165
Conditions: Allergic Reactions
At a glance
- Research payments reported, 2025
- $121,319
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 600
About the trial
- Sponsor
- ARS Pharmaceuticals, Inc.
- Tested
- Neffy (drug), Adrenaline (drug)
- Dates
- Started 2025-05-20; completion 2027-06
- Results posted
- Not yet
The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
From ClinicalTrials.gov, last updated 2026-04-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ars Pharmaceuticals Operations, Inc. reported $121,319 in research payments for this study in 2025 (22 payments).
Products named: Neffy
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Children's Hospital of Philadelphia, PA $81,456
- Icahn School of Medicine at Mount Sinai $39,863
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.